December 03, 2018 REFLECT Clinical Update with TriGUARD3 Cerebral Embolic Protection Device

Tamim Nazif

Conclusions:

• TriGUARD 3™ offers complete 3 vessel cerebral embolic protection for TAVR
• Specific design improvements optimize safety, efficacy generalizability, and ease of use of cerebral protection
• REFLECT Trial phase 2 is underway and expected to complete enrollment in early 2019
• High rate of anatomic screening success based on CT Core Lab and Patient Review Committee (>90%)